12:38 uur 21-12-2015

THERAVECTYS stelt Alain Clergeot aan als CEO

PARIS–(BUSINESS WIRE)– THERAVECTYSeen Frans volledig geïntegreerd bedrijf in onderzoek naar en klinische ontwikkeling van lentivirale therapeutische vaccins en andere immunotherapieën, konidigt met trots aan dat dokter Alain Clergeot wordt aangesteld als Chief Executive Officer. Alain Clergeot is opgeleid als arts en heeft een Executive MBA-titel op zak van de HEC. He beoefende ziekenhuisgeneeskunde in Frankrijk en in het buitenland voordat hij in 1985 ging werken voor de laboratoria van Schering-Plough. Twee jaar daarna ging hij als hoofd klinisch onderzoek aan de slag voor Bristol-Myers Squibb en later voor de oncologische business unit. In 1998 stapte hij over naar Chugai Pharmaceuticals Co. Ltd om daar een Franse tak op te zetten. Later werd hij president van Chugai Pharma Frankrijk in 2001 en gaf hij sinds 2008 operationele leiding aan de Europese tak. Hij is inmiddels vicepresident en mede-oprichter van Leem Biotech.

 

THERAVECTYS Appoints Alain Clergeot Chief Executive Officer

PARIS–(BUSINESS WIRE)– THERAVECTYS , a French biotech company specialized in lentiviral vector-based therapeutic vaccines and other immunotherapies, is pleased to announce the appointment ofAlain Clergeot, MD, as Chief Executive Officer.

Alain Clergeot is physician by training and is graduated from Executive MBA HEC. He practiced Hospital Medicine in France and abroad before joining Schering-Plough Laboratories in 1985.

Two years later he joined Bristol-Myers Squibb as head of clinical research and medical affairs before starting and managing the oncology Business Unit.

He joined Chugai Pharmaceuticals Co. Ltd in 1998 to create the French affiliate, then held Chugai Pharma France’s presidency in 2001 and the responsibility of Head of Operations Europe in 2008.

Alain is Vice-President and co-founder of the Leem Biotech, and member of the board at Paris-Biotech and former member of the Economic, Ethic and Social Board of the Haut Conseil des biotechnologies.

Alain is a seasoned professional in innovation and entrepreneurship and he demonstrated numerous achievements in the pharma and biotech fields over the last twenty five years. As Chief Executive Officer, he will provide his medical, clinical and operational expertise to further develop THERAVECTYS as a leader in immunotherapy against cancers and infectious diseases.

ABOUT THERAVECTYS

THERAVECTYS is a privately-held, fully-integrated discovery & clinical development biotech company, originating from the  Institut Pasteur. The company capitalizes on over 15 years of fundamental research in the field of lentiviral vectors and has secured worldwide exclusive rights to Pasteur Institute intellectual property. Based on its lentiviral vector technology platform, THERAVECTYS develops therapeutic vaccines and immunotherapies in oncology and infectious diseases, and has recently achieved a first Phase I/II clinical trial for its vaccine candidate against HIV.

Contacts

THERAVECTYS SA
Audrey Bonafos, +33 1 43 90 19 20
abonafos@theravectys.com
or
< b>Milestones – Press Relations
Bruno Arabian, +33 6 87 88 47 26
+33 1 83 62 34 84
barabian@miestones.fr

Check out our twitter: @NewsNovumpr